NICE provides evidenced-based guidance to improve health and social care in the United Kingdom’s National Health Service (NHS). To assess EnduraLife™-powered CRT-D devices, NICE reviewed 6 observational studies on CRT-D battery life, 5 product performance reports, 6 studies on adverse events arising from cardiac device replacement, 4 studies on cost implications of longevity and an economic model.
The National Institute for Health and Care Excellence (NICE) now recommends the use of EnduraLife™-powered CRT-Ds for treating heart failure.
NICE has stated that “The case for adopting EnduraLife™-powered CRT-D devices for treating heart failure is supported by the evidence. Extended battery life is of clinical benefit and associated with fewer replacement procedures.”
From its evaluation of this evidence, NICE concluded that the extended battery life observed with EnduraLife™-powered CRT-Ds is likely to reduce the number of avoidable replacement procedures a patient may have to undergo, thereby offering improved outcomes for patients and potential savings to the NHS in England of approximately £6 million in the first five years.
Exclusive Battery Technology
EnduraLife™ Battery Technology, which has nearly two times the usable battery capacity and is packaged in a device up to 11 percent smaller than other devices, was introduced in the company's line of CRT-Ds in 2008.